A protective role for cyclooxygenase-2 in drug-induced liver injury in mice

T P Reilly1, J N Brady, M R Marchick

  • 1Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, NHLBI, NIH, 9000 Rockville Pike, Building 10, Room 8N110, Bethesda, Maryland 20892-1760, USA. ReillyT@nhlbi.nih.gov

Insights

Cyclooxygenase-2 (COX-2) derived prostaglandins protect against acetaminophen-induced liver injury. COX inhibition, including with celecoxib, increases liver injury risk, highlighting a critical hepato-protective role for COX-2.

Area of Science:

  • Biomedical Science
  • Pharmacology
  • Toxicology

Background:

  • Cyclooxygenase (COX) inhibition is a common anti-inflammatory strategy.
  • Prostaglandins (PGs) produced by COX enzymes have regulatory roles.
  • COX inhibition may be linked to adverse drug events.

Purpose of the Study:

  • To investigate the role of endogenous COX-derived products in acetaminophen (APAP)-induced acute liver injury.
  • To determine if COX-2 plays a protective role in APAP-induced liver injury.

Main Methods:

  • Utilized a murine model of APAP-induced acute liver injury.
  • Compared hepatotoxicity and lethality in wild-type, COX-2 knockout, and heterozygous mice.
  • Administered the selective COX-2 inhibitor celecoxib to wild-type mice.
  • Analyzed gene expression using microarray analysis, focusing on heat shock proteins.

Main Results:

  • APAP selectively induced COX-2 mRNA and increased PG levels in wild-type mice.
  • Hepatotoxicity and lethality were significantly greater in COX-2 deficient mice.
  • Selective COX-2 inhibition with celecoxib mimicked the increased toxicity in wild-type mice.
  • COX-2 deficiency impaired the induction of heat shock proteins, suggesting PGs act as stress signals.

Conclusions:

  • COX-2-derived mediators play a crucial hepato-protective role against APAP-induced liver injury.
  • COX inhibition may increase the risk of drug-induced liver injury.
  • PGs may function as critical endogenous stress signals following drug insults.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...